Keyphrases
Bladder Management
100%
Antimuscarinics
100%
Overactive Bladder Symptom Score (OABSS)
100%
Mirabegron
66%
Confidence Interval
55%
Botulinum Neurotoxin (BoNT)
44%
Nerve Stimulation
44%
Treatment Options
33%
Phosphodiesterase Type 5 Inhibitors
33%
Randomized Clinical Trial
22%
Pooled Analysis
22%
Male Patients
22%
Evidence Acquisition
22%
β3-adrenoceptor Agonist
22%
Female Patients
11%
Placebo
11%
Best Medical Treatment
11%
Effective Treatment
11%
Combination Therapy
11%
Meta-analysis
11%
Patient Characteristics
11%
Pharmacological Treatment
11%
Therapeutic Approaches
11%
Phosphodiesterase Inhibitors
11%
Patient Demographics
11%
Web of Science
11%
PubMed
11%
Embase
11%
Treatment Failure
11%
Treatment Response
11%
Treatment Sequence
11%
Systematic Meta-analysis
11%
Cochrane
11%
Incontinence
11%
Scopus
11%
Interventional Treatment
11%
Cochrane Central Register of Controlled Trials
11%
Reporting Item
11%
Central Database
11%
Prospero
11%
Nocturia
11%
Neurostimulation
11%
Third-line Treatment
11%
Medical Subject Headings (MeSH)
11%
Micturition
11%
Tamsulosin
11%
Storage Symptoms
11%
Sacral Nerve Stimulation
11%
Botulinum Toxin Injection
11%
Percutaneous Tibial Nerve Stimulation
11%
Clean Intermittent Catheterization
11%
α1-blocker
11%
Clinical Scenarios
11%
INIS
patients
100%
reviews
100%
management
100%
men
100%
bladder
100%
males
70%
nerves
60%
stimulation
60%
toxins
50%
data
40%
phosphodiesterases
40%
symptoms
20%
clinical trials
20%
populations
20%
levels
10%
women
10%
reduction
10%
volume
10%
therapy
10%
females
10%
injection
10%
safety
10%
recommendations
10%
failures
10%
synthesis
10%
guidelines
10%
storage
10%
Medicine and Dentistry
Overactive Bladder
100%
Neurostimulation
75%
Mirabegron
75%
Botulinum Toxin A
50%
Systematic Review
37%
Phosphodiesterase V Inhibitor
37%
Randomized Clinical Trial
25%
Pooled Analysis
25%
Placebo
12%
Meta-Analysis
12%
Drug Therapy
12%
Combination Therapy
12%
Treatment Response
12%
Patient Population
12%
Patient Characteristics
12%
Lower Urinary Tract Symptom
12%
Sacral Nerve Stimulation
12%
Incontinence
12%
Micturition
12%
Phosphodiesterase Inhibitor
12%
Catheterization
12%
Tamsulosin
12%
Nocturia
12%
Alpha 1 Adrenergic Receptor Blocking Agent
12%
Tibial Nerve
12%
Overactive Bladder Treatment
12%
Clostridium Botulinum Type A
12%
Pharmacology, Toxicology and Pharmaceutical Science
Overactive Bladder
100%
Mirabegron
66%
Botulinum Toxin A
44%
Phosphodiesterase V Inhibitor
33%
Randomized Clinical Trial
22%
Placebo
11%
Tamsulosin
11%
Combination Therapy
11%
Lower Urinary Tract Symptom
11%
Phosphodiesterase Inhibitor
11%
Incontinence
11%
Nocturia
11%
Alpha 1 Adrenergic Receptor Blocking Agent
11%
Clostridium Botulinum Type A
11%